Jian Fang

6PUBLICATIONS
46CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 13, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial.

Wenfeng Fang, Jian Fang, Panwen Tian

|Sep 03, 2024
Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.

Jieran Long, Xuefei Li, Lin Wu

|Jul 14, 2023
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.

Tao Jiang, Qiqi Jin, Jiahao Wang

|Jun 20, 2020
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.

Di Wu, Jun Nie, Weiheng Hu

|Jun 12, 2019
Salvage treatment with anlotinib for advanced non-small cell lung cancer.

Di Wu, Jun Nie, Ling Dai

|Mar 25, 2018
Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.

Di Wu, Li Liang, Ligong Nie

Pageof 1

Frequent Collaborators

1 joint publications

Yang Wang

1 joint publications

Di Wu

1 joint publications

Tao Jiang

1 joint publications

Qiqi Jin